Vaginal microbiota and genitourinary syndrome of menopause in premenopausal breast cancer patients receiving endocrine therapy: a longitudinal cohort study protocol - Scorecard - MDSpire
Advertisement
Vaginal microbiota and genitourinary syndrome of menopause in premenopausal breast cancer patients receiving endocrine therapy: a longitudinal cohort study protocol
Clinical Scorecard: Vaginal Microbiome Changes and Genitourinary Syndrome of Menopause in Premenopausal Patients with Breast Cancer Undergoing Endocrine Therapy: A Longitudinal Study Protocol
At a Glance
Category
Detail
Condition
Key Mechanisms
Hypoestrogenism due to endocrine therapy leading to vaginal microbiome changes.
Target Population
Care Setting
Key Highlights
Endocrine therapy often induces GSM symptoms in breast cancer survivors.
Approximately 70% of patients develop GSM symptoms post-treatment.
Study compares effects of ovarian function suppression combined with aromatase inhibitors versus tamoxifen.
Guideline-Based Recommendations
Diagnosis
Assess GSM symptoms using Vaginal Health Index (VHI) and Visual Analog Scale (VAS) for dryness and dyspareunia.
Management
Endorsement of ovarian function suppression combined with aromatase inhibitors or tamoxifen as standard treatment.
Monitoring & Follow-up
Longitudinal assessment of vaginal microbiome diversity and GSM symptoms at multiple time points.
Risks
20–30% of breast cancer survivors may cease endocrine therapy due to adverse effects associated with hypoestrogenism.
Patient & Prescribing Data
110 premenopausal women with hormone receptor-positive breast cancer.
Endocrine therapy with ovarian function suppression is critical for enhancing survival outcomes.
Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.
